🛡️ One Risk Factor in Atrial Fibrillation: Is It Time for a DOAC?

🫀 AF + just one stroke-risk factor: anticoagulate or not? The SINGLE-AF randomized trial tackled this common clinical gray zone. At 24 months, the composite of stroke, systemic embolism, major bleeding, or cardiovascular death occurred in 0.5% with a DOAC vs 1.5% without anticoagulation (HR 0.31; P=0.03). 🎯 ⚠️ Only 17 primary events occurred, so the effect estimate remains imprecise. Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.pdf 💡 Takeaway: SINGLE-AF strengthens the case for DOAC therapy in selected intermediate-risk AF patients—but individualized decision-making remains essential.